B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin)
Sarah A Marshall, Kelly O'Sullivan, Hooi Hooi Ng, Ross AD Bathgate, Laura J Parry, Mohammed Akhter Hossain, Chen Huei Leo
EUROPEAN JOURNAL OF PHARMACOLOGY | ELSEVIER SCIENCE BV | Published : 2017
Recombinant H2 relaxin (serelaxin) has gained considerable attention as a new vasoprotective drug, largely due to its potential therapeutic effects in heart failure and fibrosis. However, serelaxin is laborious and costly to produce. A single-chain peptidomimetic, B7-33, has been developed to overcome these problems but little is known about its biological actions in the vascular system. This study first compared the rapid vascular effects of an acute bolus injection of B7-33 compared with serelaxin. Male Wistar rats received a tail vein injection of placebo (20mM sodium acetate), B7-33 (13.3μg/kg) or serelaxin (26.6μg/kg). Three hours later vascular function in the mesenteric artery, small ..View full abstract
Related Projects (1)
Awarded by NH & MRC Australia Project grant
This work was supported by a Ferring Innovation Grant and an NH & MRC Australia Project grant  to LJP. Research at the Florey Institute of Neuroscience and Mental Health was supported by NH & MRC Australia Project grant  to MAH and RADB and the Victorian Government Operational Infrastructure Support Program. RADB is supported by an NHMRC Research Fellowship. SAM received a University of Melbourne Research Scholarship and the David Lachlan Hay Postgraduate Writing Up-Award. HHN received a Melbourne International Research Scholarship and a Melbourne International Fee Remission Scholarship.